NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis $4.13 -0.04 (-0.96%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$4.07▼$4.2550-Day Range$2.56▼$5.7952-Week Range$0.72▼$6.10Volume184,200 shsAverage Volume488,156 shsMarket Capitalization$165.74 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Rezolute alerts: Email Address Rezolute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside134.1% Upside$9.67 Price TargetShort InterestHealthy3.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$220,314 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector299th out of 879 stocksPharmaceutical Preparations Industry136th out of 417 stocks 4.5 Analyst's Opinion Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rezolute's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.24% of the outstanding shares of Rezolute have been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rezolute has recently increased by 59.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RZLT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Rezolute this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,314.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($1.15) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Rezolute Stock (NASDAQ:RZLT)Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More RZLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLT Stock News HeadlinesJune 28, 2024 | insidertrades.comRezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Purchases 4,815 SharesJune 15, 2024 | insidertrades.comBrian Kenneth Roberts Purchases 4,300 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJuly 8, 2024 | Wealthpin Pro (Ad)Trump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.July 2, 2024 | americanbankingnews.comBrokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $9.67June 27, 2024 | globenewswire.comRezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private PlacementJune 24, 2024 | globenewswire.comRezolute Announces Closing of Public Offering with Approximately $60M in Gross ProceedsJune 13, 2024 | globenewswire.comRezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded WarrantsJune 13, 2024 | globenewswire.comRezolute Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJuly 8, 2024 | Wealthpin Pro (Ad)Trump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.May 30, 2024 | globenewswire.comRezolute to Participate in the Jefferies Global Healthcare ConferenceMay 22, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 22, 2024 | msn.comWhy Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?May 22, 2024 | markets.businessinsider.comRezolute’s RZ402 Shows Promising Efficacy and Safety in DME Treatment, Reinforcing Buy RatingMay 21, 2024 | globenewswire.comRezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 17, 2024 | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rezolute Amidst Clinical Progress and Market OpportunityMay 16, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateSee More Headlines Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/08/2024Next Earnings (Estimated)9/12/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RZLT CUSIPN/A CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$9.67 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+134.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.90% Return on Assets-54.58% Debt Debt-to-Equity RatioN/A Current Ratio11.82 Quick Ratio11.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book1.31Miscellaneous Outstanding Shares40,130,000Free Float31,787,000Market Cap$165.74 million OptionableOptionable Beta1.20 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Nevan Charles Elam J.D. (Age 57)Founder, CEO & Acting Chairman of the Board Comp: $973.65kDr. Brian Kenneth Roberts M.D. (Age 49)Chief Medical Officer Comp: $738.86kMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Financial Officer Dr. Davelyn Eaves Hood M.B.A.M.D., Director and Head of Scientific & Patient AffairsMr. Michael R. DeperroSenior VP & Head of Corporate DevelopmentMr. Michael CovarrubiasSenior VP & Head of Program & Portfolio ManagementMr. Chris MilksVP & Head of FinanceDr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical DevelopmentMs. Robyn SweinhartVP & Head of QualityMs. Erin O'BoyleSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNXeris BiopharmaNASDAQ:XERSAVEO PharmaceuticalsNASDAQ:AVEOPraxis Precision MedicinesNASDAQ:PRAXStoke TherapeuticsNASDAQ:STOKView All CompetitorsInsiders & InstitutionsWladimir HogenhuisBought 4,815 shares on 6/25/2024Total: $19,982.25 ($4.15/share)Brian Kenneth RobertsBought 4,300 shares on 6/14/2024Total: $16,813.00 ($3.91/share)Daron EvansBought 40,000 shares on 6/14/2024Total: $161,600.00 ($4.04/share)Daron EvansBought 451 shares on 5/29/2024Total: $1,578.50 ($3.50/share)Brian Kenneth RobertsBought 7,500 shares on 5/23/2024Total: $20,175.00 ($2.69/share)View All Insider TransactionsView All Institutional Transactions RZLT Stock Analysis - Frequently Asked Questions How have RZLT shares performed this year? Rezolute's stock was trading at $0.9925 on January 1st, 2024. Since then, RZLT stock has increased by 316.1% and is now trading at $4.13. View the best growth stocks for 2024 here. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO). This page (NASDAQ:RZLT) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
